{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-252200","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.192422+00:00","generated_at":"2026-05-17T01:54:02.998220+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aldeyra positive Phase 2 ADX-629 in alcohol-hepatitis; pipeline focuses on ADX-248/ADX-246; cash runway into H2 2027","bullets":["ADX-629 Phase 2 trial in mild-to-moderate alcohol-associated hepatitis showed significant improvement in MELD score (P=0.001), triglycerides (P<0.0001), and CRP (P<0.0001).","Pipeline focused on next-generation RASP modulators ADX-248 (metabolic inflammation, IND 2026) and ADX-246 (dry AMD, IND 2026); ADX-629 development discontinued.","Cash runway extended into second half of 2027 due to pipeline prioritization.","No serious adverse events reported in the ADX-629 trial; drug was well tolerated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-252200","json":"https://secwatch.observer/filing/0001193125-25-252200.json","markdown":"https://secwatch.observer/filing/0001193125-25-252200.md","text":"https://secwatch.observer/filing/0001193125-25-252200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525252200/0001193125-25-252200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525252200/aldx-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:54:02.998220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}